{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"","title":"Knowing when to sell: How growth investor Michael Frazis manages risk","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/6113c4e58b49030d2716f6e0/1788411133608-73512be8-6647-4f1a-87ec-aea9564728e3.jpeg?height=200","description":"

Michael Frazis is back to unpack a market moving faster than ever. From cracks appearing in the AI infrastructure trade and a potential software comeback, to personalised cancer vaccines and the evolution of his own investing strategy, Michael explains why he’s moved from simply holding great growth companies to systematically taking profits and managing momentum. Plus, we dig into Nvidia’s biggest long-term threat, why Apple may have played the AI boom perfectly, and the thinking behind Frazis Capital Partners’ new ROAR Active ETF.


In this episode:

00:00 Why markets could be entering a more volatile era

02:27 The AI trade, leverage & the Ashenbrenner blow-up

08:11 Is the AI infrastructure boom starting to crack?

12:25 Cheaper AI models, China & why Apple may be the winner

16:50 The software comeback & where Michael sees opportunities

22:17 Michael Frazis’ new rules for growth & momentum investing

39:25 GLP-1s, Moderna & the next wave of biotech breakthroughs

46:49 Why Frazis Capital launched the ROAR Active ETF


Stocks & ETFs Mentioned: Frazis Capital Partners ROAR Active ETF (ASX: ROAR), Nvidia (NASDAQ: NVDA), Broadcom (NASDAQ: AVGO), Apple (NASDAQ: AAPL), Alphabet (NASDAQ: GOOGL), Meta Platforms (NASDAQ: META), Amazon (NASDAQ: AMZN), Microsoft (NASDAQ: MSFT), Taiwan Semiconductor Manufacturing Company (NYSE: TSM), Alibaba Group (NYSE: BABA), Atlassian (NASDAQ: TEAM), WiseTech Global (ASX: WTC), Xero (ASX: XRO), REA Group (ASX: REA), Datadog (NASDAQ: DDOG), Tesla (NASDAQ: TSLA), AMD (NASDAQ: AMD), Palantir Technologies (NASDAQ: PLTR), Wesfarmers (ASX: WES), Commonwealth Bank (ASX: CBA), Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), Moderna (NASDAQ: MRNA), Tempus AI (NASDAQ: TEM), Clarity Pharmaceuticals (ASX: CU6)


Check out Lioncrest's new ETF ROAR here: https://lioncrestpartners.com/#roar-etf


———


Want to get involved in the podcast? Record a voice note or send us a message


And come and join the conversation in the Equity Mates Facebook Discussion Group.


———


Want more Equity Mates? Across books, podcasts, video and email, however you want to learn about investing – we’ve got you covered.

Keep up with the news moving markets with our daily newsletter and podcast (Apple | Spotify)

We’re particularly excited to share our latest show: Basis Points

Listen to the podcast (Apple | Spotify)

Watch on YouTube

Read the monthly email


———


Looking for some of our favourite research tools?

Download our free Basics of ETF handbook

Or our free 4-step stock checklist

Find company information on TIKR

Research reports from Good Research

Track your portfolio with Sharesight


———


This podcast is intended for education and entertainment purposes only. Any advice is general advice and has not taken into account your personal financial circumstances. Before acting on general advice, you should consider if it is relevant to your needs. If unsure, speak to a financial professional. The host of this podcast and their guests may have positions in the companies mentioned. Equity Mates Media is part of the Betashares Group but maintains editorial independence and operates under Australian Financial Services licence 540697.

","author_name":"Equity Mates Media"}